Abstract:
본 발명은 하기 화학식 1로 표시되는 2,2-디메틸-3-알킬에테르-4-알콕시-6-알킬 아미노벤조피란 유도체, 약제학적으로 허용 가능한 그의 염 및 그를 유효성분으로 함유하는 프로스타그란딘 E2(prostagrandine E2 ; PGE2)의 생성 억제활성 및 그로 인한 용도에 관한 것이다. 본 발명의 2,2-디메틸-3-알킬에테르-4-알콕시-6-알킬 아미노벤조피란 유도체는 PGE2의 생성에 대하여 우수한 억제활성을 나타냄을 세포 수준 및 동물실험을 통하여 규명함으로써, 상기 2,2-디메틸-3-알킬에테르-4-알콕시-6-알킬 아미노벤조피란 유도체 또는 약제학적으로 허용 가능한 그의 염을 유효성분으로 함유하여 PGE2 활성으로 유발되는 염증관련 질환 치료제 개발에 유용하다.
(상기 식에서, R 1 , R 2 , 및 R 3 는 명세서에서 정의한 바와 같다.) 아미노벤조피란, 프로스타그란딘, 산화적스트레스, 라디칼, 염증치료제
Abstract:
2,2-Dimethyl-3-alkylether-4-alkoxy-6-alkyl amino benzopyrane derivatives and PGE2(prostagrandine E2) production inhibitors containing the same compounds as an effective ingredient are provided to treat diseases associated with the activity of PGE2 by suppressing inflammation caused by PGE2. The 2,2-dimethyl-3-alkylether-4-alkoxy-6-alkyl amino benzopyrane derivatives represented by the formula(1) or their pharmaceutically acceptable salts are provided, wherein R^1 and R^2 are identical or different, and are each independently C1-C10 linear, branched or cyclic alkyl group, optionally substituted benzyl group or penethyl group; and R^3 is hydrogen, C1-C10 alkyl group, C2-C10 alkenyl group, C2-C10 alkynyl group, optionally substituted benzyl group or naphthylmethyl group. The PGE2 production inhibitors contain 2,2-dimethyl-3-alkylether-4-alkoxy-6-alkyl amino benzopyrane derivatives represented by the formula(1) or their pharmaceutically acceptable salts as effective ingredient.
Abstract:
PURPOSE: A skin external composition containing medicinal herb extract is provided to ensure suppression ability of T lymphocyte-mediated immune reaction and prevent or treat dermatitis such as atopic dermatitis, contact dermatitis and psoriasis. CONSTITUTION: A skin external composition for preventing or treat atopic dermatitis, contact dermatitis or psoriasis contains Ammomi Tsao-ko Frucuts extract as an active ingredient. The content of the Ammomi Tsao-ko Frucuts extract is 0.001~10 weight%. The skin external composition is pharmaceutical composition or cosmetic composition for treating and preventing dermatitis. The cosmetic composition is used in the form of nutrition skin, massage cream, nutrition cream, pack, gel, or essence. The dose of pharmaceutical composition is 0.001~1000 mg/kg·day.
Abstract:
A composition for external application for treating and preventing the pruritus or irritant skin disease is provided to have excellent fluxes and stability by containing the thiourea derivative and to be useful in pruritus or irritant skin disease. A composition for external application of O/w-shaped emulsion form comprises (1) drug expressed as a compound of a chemical formula 1, (2) a component selected from a group consisting of squalene, dimethicone, propylene glycol, butylene glycol and mineral oil, (3) a component selected from a group consisting of polyethylene glycol 400, polyoxyethylene alkyl ether, cetyl alcohol and solbitan stearate, (4) water and (5) a component selected from a group consisting of ethanol, twin 60, carbomer 940, EDTA.2Na and triethanolammine.
Abstract:
PURPOSE: An external use skin composition containing Dalbergiae odoriferae Lignum extract is provided to suppress the production of interleukin-4 and excessive proliferation of T-lymphocytes. CONSTITUTION: A cosmetic composition for treating T lymphocyte-mediated dermal immune diseases contains 0.001-10 weight% of Dalbergiae odoriferae Lignum extract as an active ingredient. The T lymphocyte-mediated dermal immune diseases include atopic dermatitis, contact dermatitis, or psoriasis. A pharmaceutical composition for treating T lymphocyte-mediated dermal immune diseases contains Dalbergiae odoriferae Lignum extract as an active ingredient. A dose of the pharmaceutical composition is 0.001-100mg/kg a day.